Skip to content

A camparison between Standard of care plus handheld breathing device versus only standard of care in adult bronchiectasis patients.

A Randomized Multicenter Open Label Study to Evaluate the Efficacy and Safety of Aerobika Oscillating Positive Expiratory Pressure OPEP Therapy Versus Standard of Care in Adults with Bronchiectasis - AB OPEP Bronchiectasis study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/114011
Enrollment
100
Registered
2026-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere

Interventions

Intervention1: Aerobika OPEP BID 10 min for 1 year plus Standard of Care : This device creates positive pressure with oscillation
thus secretion gets dislodged.Hence it would be easier for Bronchiectasis patient to cough out. The device is used for enrolled bronchiectasis patients along with standard of care. Control Interventio

Sponsors

Trudell Medical International
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis of bronchiectasis by HRCT of the chest 2.Documented Gram-negative bacterial infection of the respiratory tract 3.At least one documented bronchiectasis exacerbation requiring systemic antibiotics or systemic corticosteroids within the 12 months prior to screening 4.Clinically stable for at least 4 weeks prior to randomization 5.Able to perform and reproducibly complete spirometry according to ATS ERS criteria 6.Provision of written informed consent prior to any study specific procedure 7.Patients have never used any kind of OPEP device in the past.

Exclusion criteria

Exclusion criteria: 1.History of pneumothorax within the preceding 3 months or known bullous emphysema constituting a contraindication to positive pressure techniques 2.Massive hemoptysis within the preceding 3 months 3.Significant neuromuscular or cognitive impairment precluding safe and effective device use as judged by the investigator 4.Current enrolment in another interventional randomized control trial 5.Pregnancy or planned pregnancy during the study period or breastfeeding 6.Any other medical condition that in the opinion of the investigator would prevent safe participation or confound study interpretation

Design outcomes

Primary

MeasureTime frame
Bronchiectasis Health QuestionnaireTimepoint: 6 months

Secondary

MeasureTime frame
1.Exacerbation Outcomes 2.Physiological Outcomes 3.Patient Reported Symptom Outcomes 4.Safety OutcomesTimepoint: 6 months and 12 months

Countries

India

Contacts

Public ContactDr Raja Dhar

The Calcutta Medical Research Institute

pulmoresearch@gmail.com9831855512

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026